271 related articles for article (PubMed ID: 19526965)
41. Hepatitis B treatment: Current best practices, avoiding resistance.
Gish RG
Cleve Clin J Med; 2009 May; 76 Suppl 3():S14-9. PubMed ID: 19465704
[TBL] [Abstract][Full Text] [Related]
42. Experts call for new trials of hepatitis B drugs: evidence needed to identify first-line treatment.
Traynor K
Am J Health Syst Pharm; 2008 Dec; 65(23):2184, 2186. PubMed ID: 19020176
[No Abstract] [Full Text] [Related]
43. Hepatitis B infection in an HIV-positive man treated with tenofovir: a case of re-infection or reactivation?
Richardson D; Lamba H
Int J STD AIDS; 2004 Mar; 15(3):204-5. PubMed ID: 15038871
[TBL] [Abstract][Full Text] [Related]
44. Chronic hepatitis B: back to the future with HBsAg.
Moucari R; Lada O; Marcellin P
Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
[No Abstract] [Full Text] [Related]
45. Drug therapy: tenofovir.
Lok AS
Hepatology; 2010 Aug; 52(2):743-7. PubMed ID: 20597070
[No Abstract] [Full Text] [Related]
46. Prevention of hepatocellular carcinoma.
Craxì A; Cammà C
Clin Liver Dis; 2005 May; 9(2):329-46, viii. PubMed ID: 15831277
[TBL] [Abstract][Full Text] [Related]
47. Treatment of chronic hepatitis B and the implications of viral resistance to therapy.
Mauss S; Wedemeyer H
Expert Rev Anti Infect Ther; 2008 Apr; 6(2):191-9. PubMed ID: 18380601
[TBL] [Abstract][Full Text] [Related]
48. Tenofovir disoproxil fumarate: role in hepatitis B treatment.
Wong SN; Lok AS
Hepatology; 2006 Aug; 44(2):309-13. PubMed ID: 16871562
[No Abstract] [Full Text] [Related]
49. Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?
Lim LY; Kowdley KV
Gastroenterology; 2005 Dec; 129(6):2120-2; discussion 2122. PubMed ID: 16344085
[No Abstract] [Full Text] [Related]
50. Two-year data released on Viread for chronic hepatitis B.
AIDS Patient Care STDS; 2008 Nov; 22(11):921. PubMed ID: 19025487
[No Abstract] [Full Text] [Related]
51. Defining optimal therapeutic outcomes in chronic hepatitis.
Lisker-Melman M; Sayuk GS
Arch Med Res; 2007 Aug; 38(6):652-60. PubMed ID: 17613357
[TBL] [Abstract][Full Text] [Related]
52. Review article: current antiviral therapy of chronic hepatitis B.
Ayoub WS; Keeffe EB
Aliment Pharmacol Ther; 2011 Nov; 34(10):1145-58. PubMed ID: 21978243
[TBL] [Abstract][Full Text] [Related]
53. [Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
Kato N; Goto T; Omata M
Nihon Naika Gakkai Zasshi; 2008 Jan; 97(1):50-6. PubMed ID: 18360970
[No Abstract] [Full Text] [Related]
54. Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?
Lau GK
J Hepatol; 2007 Jan; 46(1):6-8. PubMed ID: 17112628
[No Abstract] [Full Text] [Related]
55. FDA notifications. FDA's tentative approval for generic Tenofovir.
AIDS Alert; 2008 Jan; 23(1):11-2. PubMed ID: 18572475
[No Abstract] [Full Text] [Related]
56. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
European Association For The Study Of The Liver
J Hepatol; 2012 Jul; 57(1):167-85. PubMed ID: 22436845
[No Abstract] [Full Text] [Related]
57. [New advances in the treatment of chronic hepatitis B: position of entecavir].
Olaso V
Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
[No Abstract] [Full Text] [Related]
58. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?
Howell J; Chan HLY; Feld JJ; Hellard ME; Thompson AJ
Gastroenterology; 2020 Jun; 158(8):2028-2032. PubMed ID: 32088205
[No Abstract] [Full Text] [Related]
59. New treatment approved for chronic hepatitis B.
FDA Consum; 2002; 36(6):4-5. PubMed ID: 12523284
[No Abstract] [Full Text] [Related]
60. Antiviral therapy after curative resection for patients with hepatitis B-related hepatocellular carcinoma.
Chong CC; Lai PB
Br J Surg; 2013 May; 100(6):724-5. PubMed ID: 23475744
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
